Q4 EPS Estimates for Legend Biotech Cut by HC Wainwright

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) – HC Wainwright cut their Q4 2026 EPS estimates for shares of Legend Biotech in a research report issued on Wednesday, July 15th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of $0.22 per share for the quarter, down from their previous estimate of $0.26. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Legend Biotech’s current full-year earnings is ($0.01) per share.

LEGN has been the subject of several other research reports. Truist Financial downgraded shares of Legend Biotech from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 20th. JPMorgan Chase & Co. assumed coverage on Legend Biotech in a research report on Monday, July 13th. They set a “neutral” rating and a $35.00 target price on the stock. Morgan Stanley reduced their target price on Legend Biotech from $49.00 to $48.00 and set an “overweight” rating for the company in a report on Wednesday, May 13th. UBS Group upped their target price on Legend Biotech from $31.00 to $49.00 and gave the company a “buy” rating in a research report on Wednesday, June 3rd. Finally, Royal Bank Of Canada dropped their price target on Legend Biotech from $64.00 to $63.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 7th. Nine analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $57.00.

Legend Biotech Price Performance

Shares of NASDAQ:LEGN opened at $22.26 on Friday. Legend Biotech has a 12 month low of $16.24 and a 12 month high of $45.30. The firm has a market capitalization of $4.13 billion, a P/E ratio of -32.73 and a beta of 0.34. The company’s fifty day moving average price is $29.33 and its 200 day moving average price is $23.32.

Legend Biotech (NASDAQ:LEGN) last issued its earnings results on Wednesday, May 13th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.01). The company had revenue of $305.10 million during the quarter, compared to analyst estimates of $306.51 million. Legend Biotech had a negative net margin of 21.98% and a negative return on equity of 24.92%. The company’s quarterly revenue was up 56.5% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.07) EPS.

Institutional Investors Weigh In On Legend Biotech

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Suvretta Capital Management LLC grew its holdings in shares of Legend Biotech by 73.1% during the fourth quarter. Suvretta Capital Management LLC now owns 6,608,629 shares of the company’s stock worth $143,672,000 after buying an additional 2,790,620 shares during the last quarter. Westfield Capital Management Co. LP raised its stake in Legend Biotech by 1.2% during the 4th quarter. Westfield Capital Management Co. LP now owns 6,164,677 shares of the company’s stock valued at $134,020,000 after acquiring an additional 70,191 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in Legend Biotech by 120.5% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,174,535 shares of the company’s stock valued at $47,274,000 after acquiring an additional 1,188,449 shares during the last quarter. Assenagon Asset Management S.A. acquired a new stake in Legend Biotech during the 2nd quarter worth approximately $55,307,000. Finally, Alliancebernstein L.P. lifted its position in Legend Biotech by 4.6% during the 3rd quarter. Alliancebernstein L.P. now owns 1,632,967 shares of the company’s stock worth $53,251,000 after acquiring an additional 72,371 shares during the period. 70.89% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CEO Ying Huang sold 5,566 shares of the stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $14.78, for a total transaction of $82,265.48. Following the completion of the sale, the chief executive officer owned 241,872 shares in the company, valued at $3,574,868.16. This represents a 2.25% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.02% of the stock is currently owned by corporate insiders.

Legend Biotech Company Profile

Legend Biotech (NASDAQ: LEGN) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson.

The company’s lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)–directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma.